Pharmaceutical products

Tender description

The NHS Commissioning Board (operating under the name of NHS England and NHS Improvement) has established an NHS framework agreement (on behalf of NHS Trusts) for the supply of drugs licensed specifically to target epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer. Ref: tender C1485 Period of framework: 1 December 2020* to 30 November 2022 with an option to extend (at the authority’s discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 36 months). The NHS Commissioning Board (operating under the name of NHS England and NHS Improvement) has established an NHS framework agreement (on behalf of NHS Trusts) for the supply of drugs licensed specifically to target epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer. Ref: tender C1485 Period of framework: 1 December 2020* to 30 November 2022 with an option to extend (at the authority’s discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 36 months).